| Question 1: In the published MR guided prostate SBRT the rate of GI toxicity ? G2 at 1 year was: |
| Reference: | Reference: Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study
Shyama U. Tetar, Anna M.E. Bruynzeel, Swie S. Oei, Suresh Senan, Tamara Fraikin, Berend J. Slotman, R. Jeroen A. van Moorselaar, Frank J. Lagerwaard, European Urology Oncology, 2020 MD Cancer, Vol 122, Issue 11, pp 1659-1671, 2016 |
| Choice A: | 0% |
| Choice B: | 5% |
| Choice C: | 10% |
| Choice D: | 15% |
| Question 2: Early reports suggest 20 Gy single fraction breast MRgRT was: |
| Reference: | Reference: Kennedy WR, Thomas MA, Stanley JA, Luo J, Ochoa LL, Clifton KK, Cyr AE, Margenthaler JA, DeWees TA, Price A, Kashani R, Green O, Zoberi I. Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer. Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):344-352. doi: 10.1016/j.ijrobp.2020.02.021. Epub 2020 Feb 19. PMID: 32084524. |
| Choice A: | Tolerated well, but cosmesis was poor. |
| Choice B: | Tolerated well, and cosmesis was good. |
| Choice C: | Tolerated poorly, and cosmesis was poor. |
| Choice D: | Tolerated poorly, but cosmesis was good. |
| Question 3: Which of the following is potentially one of the MOST transformational aspects of MR Guidance for the future of RT? |
| Reference: | Reference: van Houdt PJ, Front Oncol. 2021 Jan 29;10:615643. doi: 10.3389/fonc.2020.615643. eCollection 2020. |
| Choice A: | Patient repositioning, accounting for change of normal organ positioning |
| Choice B: | Routine access to MR based biological imaging (functional and quantitative) without inconvenience to the patient |
| Choice C: | Ability to perform preoperative pancreatic SBRT without fiducials |
| Choice D: | MR guidance is not relevant for the future of RT |
| Question 4: Which of the following clinical circumstances offers a potential advantage of MR Guided radiation therapy over CT based radiation therapy? |
| Reference: | Reference: Robins. Semin Radiat Oncol. 2018 Oct;28(4):288-294 |
| Choice A: | A 1.5 cm dome of the liver colorectal oligometastatic lesion, difficult to visualize on CT, in a patient with contraindications to fiducial placement |
| Choice B: | Stage III primary non-small cell lung cancer |
| Choice C: | Rectal cancer planned for pre-operative external beam radiation therapy, without plans for organ preservation |
| Choice D: | A single brain metastasis that has been resected |
| Question 5: Regarding treating a patient with a pacemaker on an 0.35T MRIgRT system: |
| Reference: | Reference: Wilkoff, Bruce L., et al. "Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment." Heart rhythm 8.1 (2011): 65-73. |
| Choice A: | MRI scanning is never allowed, pacemaker is an absolute contraindication to MRI |
| Choice B: | If the pacemaker is FDA-cleared for 1.5T only, the manufacturer will support scanning at 0.35T because the lower field is less risky |
| Choice C: | If the patient is not pacemaker dependent, no additional actions are needed. |
| Choice D: | Factors potentially affecting the safety of scanning include the field strength, slew rate, SAR, and location of the pacemaker with respect to the RF transmit coil isocenter. |
| Question 6: Visual bio-feedback for patient-controlled respiratory MR image-based gating has demonstrated: |
| Reference: | Reference: Lee, Danny, et al. "Audiovisual biofeedback guided breath hold improves lung tumor position reproducibility and volume consistency." Advances in radiation oncology 2.3 (2017): 354-362. |
| Choice A: | No benefit to the patient |
| Choice B: | Statistically significant reduction in gated treatment times. |
| Choice C: | No measurable reduction in image quality metrics. |
| Choice D: | Statically significantly improved dosimetric accuracy of gated treatments. |
